News & Media
Forge Enters Into Collaboration with Roche to Develop Novel Antibiotic to Treat Lung Infections
Forge is eligible to receive $190.5M in total payments SAN DIEGO, California, March 25, 2020 ...
Forge Therapeutics receives notice of allowance from U.S. patent and trademark office covering novel chemistry targeting LpxC for the treatment of gram-negative bacterial infections
-Issuance of patent demonstrates utility of Forge’s BLACKSMITH chemistry platform- San Diego, California, Aug ...
Forge And Basilea Enter Into Multi-Target Agreement To Discover And Develop Novel Antibiotics
San Diego, California, April 24, 2019 – Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International ...
Forge Therapeutics to present at the 18th Annual Needham & Company Healthcare Conference
-Presentation will focus on Forge’s novel chemistry platform, BLACKSMITH, and its therapeutic applications- San Diego, ...
Forge Receives Second CARB-X Award For Up To $11.1M To Accelerate Development Of Novel Antibiotic To Treat Lung Infections
San Diego, California, January 3, 2019 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing ...
